Compare NOVTU & MDAIW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NOVTU | MDAIW |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | 3000 | 78 |
| Industry | Industrial Machinery/Components | Medical/Dental Instruments |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | N/A |
| Metric | NOVTU | MDAIW |
|---|---|---|
| Price | $60.71 | $0.41 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 17.9K | 9.4K |
| Earning Date | N/A | 02-27-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,264,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 44.52 |
| 52 Week Low | $47.57 | $0.26 |
| 52 Week High | $64.51 | $1.01 |
| Indicator | NOVTU | MDAIW |
|---|---|---|
| Relative Strength Index (RSI) | 50.83 | 35.54 |
| Support Level | $58.54 | $0.37 |
| Resistance Level | $61.73 | $0.61 |
| Average True Range (ATR) | 1.43 | 0.06 |
| MACD | -0.41 | -0.01 |
| Stochastic Oscillator | 49.52 | 5.29 |
Novanta Inc manufactures photonic and motion-control components for original equipment manufacturers in the medical equipment and industrial technology markets. The firm operates in two segments: Automation Enabling Technologies and Medical Solutions. It generates the majority of its revenue from the Medical Solutions segment that designs, manufactures, and markets a range of medical-grade technologies, including medical insufflators, pumps, and related disposables; visualization solutions; and wireless technologies. The firm generates the majority of its revenue from the United States and Europe.
Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely, and informed decision regarding the treatment of the patient's wound.